These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37079341)

  • 21. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gaillard S; Oaknin A; Ray-Coquard I; Vergote I; Scambia G; Colombo N; Fernandez C; Alfaro V; Kahatt C; Nieto A; Zeaiter A; Aracil M; Vidal L; Pardo-Burdalo B; Papai Z; Kristeleit R; O'Malley DM; Benjamin I; Pautier P; Lorusso D
    Gynecol Oncol; 2021 Nov; 163(2):237-245. PubMed ID: 34521554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
    Rittberg R; Leung B; Al-Hashami Z; Ho C
    Curr Oncol; 2022 Dec; 29(12):9744-9752. PubMed ID: 36547179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
    Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
    Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
    Amarasena IU; Chatterjee S; Walters JA; Wood-Baker R; Fong KM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006849. PubMed ID: 26233609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
    Singh S; Jaigirdar AA; Mulkey F; Cheng J; Hamed SS; Li Y; Liu J; Zhao H; Goheer A; Helms WS; Wang X; Agarwal R; Pragani R; Korsah K; Tang S; Leighton J; Rahman A; Beaver JA; Pazdur R; Theoret MR; Singh H
    Clin Cancer Res; 2021 May; 27(9):2378-2382. PubMed ID: 33288660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
    Shinn LT; Vo KA; Reeves DJ
    Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
    Amarasena IU; Walters JA; Wood-Baker R; Fong K
    Cochrane Database Syst Rev; 2008 Oct; (4):CD006849. PubMed ID: 18843733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
    Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
    Poveda A; Del Campo JM; Ray-Coquard I; Alexandre J; Provansal M; Guerra Alía EM; Casado A; Gonzalez-Martin A; Fernández C; Rodriguez I; Soto A; Kahatt C; Fernández Teruel C; Galmarini CM; Pérez de la Haza A; Bohan P; Berton-Rigaud D
    Ann Oncol; 2017 Jun; 28(6):1280-1287. PubMed ID: 28368437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
    Dumoulin DW; Cantini L; Cornelissen R; Vink M; Klaase L; Slooff K; Tebayna N; Mankor JM; Baart SJ; Hendriks R; Dingemans AC; Willemsen M; Aerts JGJV
    Eur J Cancer; 2022 Sep; 172():357-366. PubMed ID: 35834843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
    Das M; Padda SK; Weiss J; Owonikoko TK
    Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
    Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
    Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update 2021: Management of Small Cell Lung Cancer.
    Tariq S; Kim SY; Monteiro de Oliveira Novaes J; Cheng H
    Lung; 2021 Dec; 199(6):579-587. PubMed ID: 34757446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
    Horiuchi K; Sato T; Kuno T; Takagi H; Hirsch FR; Powell CA; Fukunaga K
    Lung Cancer; 2021 Jun; 156():59-67. PubMed ID: 33894495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
    Rajput PS; Khan SR; Singh P; Chawla PA
    Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
    Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
    J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
    Smare C; Dave K; Juarez-Garcia A; Abraham P; Penrod JR; Camidge DR; Yuan Y
    J Med Econ; 2021; 24(1):1124-1133. PubMed ID: 34465261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lurbinectedin in small cell lung cancer.
    Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
    Front Oncol; 2022; 12():932105. PubMed ID: 36110944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
    von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
    J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.